Barclays’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $53.4M | Sell |
247,157
-304,317
| -55% | -$58.2M | 0.01% | 707 |
|
|
2026
Q1 | $101M | Sell |
551,474
-753,533
| -58% | -$139M | 0.02% | 483 |
|
|
2025
Q4 | $230M | Sell |
1,305,007
-54,417
| -4% | -$8.89M | 0.06% | 258 |
|
|
2025
Q3 | $190M | Buy |
1,359,424
+561,769
| +70% | +$75.9M | 0.04% | 306 |
|
|
2025
Q2 | $100M | Sell |
797,655
-120,698
| -13% | -$15M | 0.02% | 471 |
|
|
2025
Q1 | $126M | Buy |
918,353
+79,999
| +10% | +$11.4M | 0.04% | 353 |
|
|
2024
Q4 | $128M | Sell |
838,354
-82,902
| -9% | -$14M | 0.04% | 332 |
|
|
2024
Q3 | $179M | Buy |
921,256
+473,603
| +106% | +$99.1M | 0.05% | 280 |
|
|
2024
Q2 | $104M | Sell |
447,653
-92,912
| -17% | -$20.2M | 0.03% | 372 |
|
|
2024
Q1 | $117M | Buy |
540,565
+8,305
| +2% | +$1.95M | 0.04% | 346 |
|
|
2023
Q4 | $138M | Buy |
532,260
+136,584
| +35% | +$33.5M | 0.05% | 320 |
|
|
2023
Q3 | $102M | Sell |
395,676
-192,085
| -33% | -$51.4M | 0.06% | 310 |
|
|
2023
Q2 | $167M | Buy |
587,761
+129,918
| +28% | +$38.7M | 0.11% | 175 |
|
|
2023
Q1 | $127M | Sell |
457,843
-164,885
| -26% | -$45.6M | 0.06% | 216 |
|
|
2022
Q4 | $172M | Buy |
622,728
+286,871
| +85% | +$81M | 0.08% | 179 |
|
|
2022
Q3 | $89.7M | Buy |
335,857
+23,342
| +7% | +$4.96M | 0.1% | 194 |
|
|
2022
Q2 | $63.7M | Sell |
312,515
-66,866
| -18% | -$13.7M | 0.04% | 319 |
|
|
2022
Q1 | $79.9M | Sell |
379,381
-437,190
| -54% | -$95.1M | 0.06% | 287 |
|
|
2021
Q4 | $196M | Buy |
816,571
+431,657
| +112% | +$111M | 0.07% | 220 |
|
|
2021
Q3 | $109M | Buy |
384,914
+56,681
| +17% | +$18.6M | 0.05% | 296 |
|
|
2021
Q2 | $114M | Buy |
328,233
+32,878
| +11% | +$9.96M | 0.05% | 266 |
|
|
2021
Q1 | $82.6M | Sell |
295,355
-205,329
| -41% | -$55.4M | 0.04% | 307 |
|
|
2020
Q4 | $123M | Buy |
500,684
+81,422
| +19% | +$21M | 0.06% | 232 |
|
|
2020
Q3 | $119M | Buy |
419,262
+40,253
| +11% | +$11.2M | 0.07% | 200 |
|
|
2020
Q2 | $101M | Sell |
379,009
-20,026
| -5% | -$6.02M | 0.08% | 190 |
|
|
2020
Q1 | $126M | Sell |
399,035
-265,491
| -40% | -$80.6M | 0.1% | 136 |
|
|
2019
Q4 | $197M | Buy |
664,526
+139,725
| +27% | +$38.8M | 0.11% | 149 |
|
|
2019
Q3 | $122M | Buy |
524,801
+14,557
| +3% | +$3.39M | 0.08% | 203 |
|
|
2019
Q2 | $119M | Buy |
510,244
+119,272
| +31% | +$27.5M | 0.07% | 221 |
|
|
2019
Q1 | $92.4M | Sell |
390,972
-3,223
| -0.8% | -$1.01M | 0.06% | 257 |
|
|
2018
Q4 | $119M | Buy |
394,195
+54,310
| +16% | +$17.3M | 0.09% | 156 |
|
|
2018
Q3 | $120M | Sell |
339,885
-13,556
| -4% | -$4.67M | 0.08% | 176 |
|
|
2018
Q2 | $103M | Sell |
353,441
-117,833
| -25% | -$33.1M | 0.09% | 187 |
|
|
2018
Q1 | $129M | Buy |
471,274
+161,284
| +52% | +$50.1M | 0.1% | 169 |
|
|
2017
Q4 | $98.8M | Buy |
309,990
+156,148
| +101% | +$50.1M | 0.08% | 205 |
|
|
2017
Q3 | $48.2M | Sell |
153,842
-55,128
| -26% | -$16.3M | 0.05% | 306 |
|
|
2017
Q2 | $56.7M | Buy |
208,970
+49,430
| +31% | +$13.1M | 0.06% | 246 |
|
|
2017
Q1 | $43.6M | Sell |
159,540
-7,558
| -5% | -$2.14M | 0.05% | 292 |
|
|
2016
Q4 | $47.4M | Buy |
167,098
+15,845
| +10% | +$4.7M | 0.05% | 289 |
|
|
2016
Q3 | $47.3M | Sell |
151,253
-30,197
| -17% | -$8.94M | 0.05% | 267 |
|
|
2016
Q2 | $43.9M | Sell |
181,450
-78,751
| -30% | -$20.8M | 0.06% | 281 |
|
|
2016
Q1 | $67.7M | Sell |
260,201
-86,407
| -25% | -$22.8M | 0.1% | 158 |
|
|
2015
Q4 | $106M | Sell |
346,608
-203,556
| -37% | -$58.5M | 0.13% | 136 |
|
|
2015
Q3 | $160M | Buy |
550,164
+152,755
| +38% | +$50.4M | 0.19% | 80 |
|
|
2015
Q2 | $160M | Buy |
397,409
+10,484
| +3% | +$4.21M | 0.18% | 82 |
|
|
2015
Q1 | $163M | Buy |
386,925
+125,855
| +48% | +$49.6M | 0.19% | 84 |
|
|
2014
Q4 | $88.5M | Buy |
261,070
+56,120
| +27% | +$18.2M | 0.09% | 191 |
|
|
2014
Q3 | $67.6M | Buy |
204,950
+23,485
| +13% | +$7.74M | 0.07% | 245 |
|
|
2014
Q2 | $57.2M | Sell |
181,465
-261,702
| -59% | -$78.8M | 0.06% | 268 |
|
|
2014
Q1 | $135M | Sell |
443,167
-224,777
| -34% | -$71.4M | 0.15% | 107 |
|
|
2013
Q4 | $186M | Buy |
667,944
+350,543
| +110% | +$90.7M | 0.19% | 69 |
|
|
2013
Q3 | $76.2M | Buy |
317,401
+145,616
| +85% | +$32.6M | 0.09% | 185 |
|
|
2013
Q2 | $37M | Buy |
+171,785
| New | +$36.7M | 0.05% | 358 |
|
Other funds holding BIIB
Barclays's BIIB Position: Q2 2026 in Review
Barclays reduced its Biogen (BIIB) stake by 55% in Q2 2026, selling an estimated $58.2M and leaving 247,157 shares worth $53.4M. The position accounts for 0.01% of the portfolio, ranked #707.
Barclays first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $230M in Q4 2025. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Barclays held 247,157 shares of Biogen worth $53.4M as of Q2 2026.
- Barclays sold 304,317 Biogen shares in Q2 2026, an estimated $58.2M.
- Biogen made up 0.01% of Barclays's portfolio in Q2 2026, its #707 holding.
- Barclays first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
- Barclays's Biogen position peaked at $230M in Q4 2025.
- 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.